Tirzepatide (LY3298176) | CAS 2023788-19-2 | Dual GIP/GLP-1 Receptor Agonist | Knowlux

Product Description

Tirzepatide, CAS 2023788-19-2, is a synthetic dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist supplied by Knowlux. It is a 39-amino-acid peptide with a C20 fatty diacid side chain that enables albumin binding and a prolonged half-life, supporting once-weekly administration. The molecular formula is C225H348N48O68 and the molecular weight is 4813.45 g/mol (free base). Each lot is released with a lot-specific COA, MSDS and full analytical traceability.

Product Parameters

Product Details

1. Overview

Tirzepatide (LY3298176) is the first dual agonist of the GIP and GLP-1 receptors, approved in the US and EU for the treatment of type 2 diabetes mellitus and for weight management in obesity or overweight patients with at least one weight-related comorbid condition . It is a 39-amino-acid peptide engineered with a C20 fatty diacid side chain that promotes albumin binding and extends the half-life to support once-weekly subcutaneous dosing. Unlike selective GLP-1 receptor agonists, tirzepatide shows greater engagement at the GIP receptor than at the GLP-1 receptor, an “imbalanced” pharmacology that is thought to contribute to its enhanced metabolic efficacy .

2. Mechanism of Action

Tirzepatide activates both GIP and GLP-1 receptors, producing glucose-dependent insulin secretion, suppression of glucagon release, slowing of gastric emptying, and reduced appetite through central signalling . Preclinical signalling studies indicate that tirzepatide mimics native GIP at the GIP receptor while showing biased agonism at the GLP-1 receptor, favouring cAMP generation over β-arrestin recruitment, which may enhance insulinotropic activity . Clinical data demonstrate dose- and duration-dependent reductions in HbA1c and body weight, with weight reduction reaching up to approximately 20% in comparative studies .

3. Quality Control

Full COA, MSDS, and lot-specific chromatograms are issued with each shipment. Custom specifications and third-party inspection can be arranged.

4. Applications

• Reference standard and impurity studies for dual incretin receptor agonist analytical methods

• GIPR and GLP-1R binding and functional assay development

• Formulation development for long-acting injectable peptides

• Metabolic disease model research, including obesity, glucose homeostasis and cardiovascular risk biomarker studies

• LC-MS, immunoassay and bioassay calibrators

5. Packaging, Storage & Shipping

Lyophilized powder: amber glass vial under nitrogen headspace, sealed with butyl stopper and aluminium crimp. Secondary packing: tamper-evident, light-protected carton with desiccant. Cold-chain shipping with validated gel packs and temperature logger; dry ice for -20 °C shipments. COA, MSDS, packing list and certificate of origin issued with each shipment.

6. Documentation Support

Per lot: COA, MSDS, certificate of origin, GMO/allergen-free statement, residual solvent statement. Regulatory packages (specification summaries, audit support) available on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

This product is supplied for pharmaceutical research and development use by licensed organisations only. It is not for direct human or veterinary administration, not for retail sale, and not for personal use. Mechanism and clinical development statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.